4.6 Review

NF-kB and the CLL microenvironment

期刊

FRONTIERS IN ONCOLOGY
卷 13, 期 -, 页码 -

出版社

FRONTIERS MEDIA SA
DOI: 10.3389/fonc.2023.1169397

关键词

chronic lymphocytic leukemia; NF-kappaB signaling pathway; tumor microenvironment; hematological malignancies; therapeutic targets; CLL

类别

向作者/读者索取更多资源

Chronic lymphocytic leukemia (CLL) is a common and incurable type of leukemia. The Nuclear Factor-Kappa B (NF-kappa B) transcription factor plays a role in CLL, with high levels associated with disease progression and drug resistance. Genetic mutations and microenvironmental factors activate NF-kappa B through two distinct pathways, leading to tumor cell survival and resistance to treatment. Understanding how the CLL microenvironment drives NF-kappa B activation is crucial for developing new therapeutic approaches.
Chronic lymphocytic leukemia (CLL) is the most prevalent type of leukemia in the western world. Despite the positive clinical effects of new targeted therapies, CLL still remains an incurable and refractory disease and resistance to treatments are commonly encountered. The Nuclear Factor-Kappa B (NF-kappa B) transcription factor has been implicated in the pathology of CLL, with high levels of NF-kappa B associated with disease progression and drug resistance. This aberrant NF-kappa B activation can be caused by genetic mutations in the tumor cells and microenvironmental factors, which promote NF-kappa B signaling. Activation can be induced via two distinct pathways, the canonical and non-canonical pathway, which result in tumor cell proliferation, survival and drug resistance. Therefore, understanding how the CLL microenvironment drives NF-kappa B activation is important for deciphering how CLL cells evade treatment and may aid the development of novel targeting therapeutics. The CLL microenvironment is comprised of various cells, including nurse like cells, mesenchymal stromal cells, follicular dendritic cells and CD4+ T cells. By activating different receptors, including the B cell receptor and CD40, these cells cause overactivity of the canonical and non-canonical NF-kappa B pathways. Within this review, we will explore the different components of the CLL microenvironment that drive the NF-kappa B pathway, investigating how this knowledge is being translated in the development of new therapeutics.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据